Reviews/Omega-3 Fatty Acids/Omega-3 for dry eye
Inflam · OMEGA-INFLAM-02 · v2
Borderline: within 4 points of the Uncertain/Doubtful boundary, so a re-grade could land either side.
Most of the trials in this corpus that gave people omega-3 capsules by mouth reported that dry eye symptoms got better. But the single largest and most carefully run trial [1], with 535 patients, found no difference between omega-3 and placebo. The smaller positive trials have weaknesses: several come from the same research group, some compared omega-3 against oils that are not truly inert, one combined omega-3 with another fatty acid, and many studied narrow groups such as computer users or contact-lens wearers. So the evidence points in both directions at once. The panel landed in the middle because the best-quality study disagreed with the larger number of lower-quality studies.
Several randomised trials report that oral omega-3 improves symptoms: a responder rate of 65% versus 33% on placebo [2], a symptom-score improvement of 4.7 versus 0.5 [7], an OSDI reduction of -17.0 versus -5.0 against a linoleic-acid control [8], and benefit in the krill-oil arm (-18.6 vs -10.5, P=0.02) [10], with secondary symptom improvement in VDT users [3] and omega-3-index-deficient patients [11], and a subgroup benefit in extremely symptomatic participants [5]. Against this, the largest and most rigorous trial [1] (N=535) found no symptom benefit (mean difference -1.9; 95% CI -5.0 to 1.1; P=0.21) and no benefit on any sign. Open-label adjunct use after cataract surgery also improved OSDI [9]. The positive trials cluster in specific populations and some share authorship. The contested point: The division is between the quantity of positive trials and the quality of the one null trial: many smaller, lower-independence studies show symptom benefit while the single best-powered, independently funded trial [1] shows none. Whether the weight of numerous positive but confounded trials should override one rigorous null result is the point on which the evidence and the panel divide.
All 11 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Omega-3 Fatty Acids, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The largest, best-powered, independently funded RCT [1] (N=535) found no symptom benefit and no benefit on any sign, directly contradicting the claim; it should outweigh the many smaller positive trials.
Several positive trials ([3],[4],[7],[11]) share overlapping authorship (Bhargava and colleagues), so the apparent weight of positive replication overstates evidential independence.
Where it remains uncertain. The flagship DREAM trial [1] (N=535) found no symptom benefit (difference -1.9; 95% CI -5.0 to 1.1; P=0.21), and the positive trials are weakened by shared authorship, active-oil comparators, a combination product [5], and niche populations.
Aleatory
Many positive trials are small (e.g. N=50 completed in [5], N=60 in [10]), so individual results carry wide play-of-chance that larger trials like [1] do not.
Epistemic
Positive trials [3],[4],[7],[11] share overlapping authorship (Bhargava and colleagues), so the count of positive studies overstates how much independent confirmation exists.
Inferential
Positive trials are confined to VDT users [3],[4], contact-lens wearers [7], post-phacoemulsification patients [9] and omega-3-deficient patients [11], while the null trial [1] studied general moderate-to-severe disease, so extending either result to the other population is an inference the corpus does not close.
The load-bearing papers from a corpus of 11, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Highest-quality, best-powered trial contradicts the claim on the symptom endpoint
“The mean change in the OSDI score was not significantly different between the active supplement group and the placebo group (-13.9 points and -12.5 points, respectively; mean difference in change after imputation of missing data, -1.9 points; 95% confidence interval [CI], -5.0 to 1.1; P=0.21).”
Panel auditInternal validity: high · scope of inference: Patients with moderate-to-severe dry eye disease taking high-dose oral n-3 for 12 months.Key limitations: single trial, one dose/formulation · moderate-to-severe DED only
Placebo-controlled symptom responder benefit
“Sixty-five percent of patients in the omega-3 group and 33% of patients in placebo group had significant improvement in symptoms at 3 months (P=0.005).”
Panel auditInternal validity: medium · scope of inference: Dry eye syndrome patients, with benefit noted as more marked in blepharitis and meibomian gland disease.Key limitations: eye-level randomization · short 3-month follow-up
Symptom benefit in computer-vision-syndrome DED
“This study demonstrates the beneficial effect of orally administered O3FAs in alleviating dry eye symptoms, decreasing tear evaporation rate and improving Nelson grade in patients suffering from computer vision syndrome related dry eye.”
Panel auditInternal validity: medium · scope of inference: Patients with computer vision syndrome related dry eye using computers over 3 hours per day.Key limitations: no reported significance test for symptoms · short follow-up
Symptom improvement (secondary) in VDT users
“In the O3FA group, a significant increase in omega-3 index, improvement in symptoms, reduction in tear film osmolarity, and increase in Schirmer, TBUT, and goblet cell density was observed.”
Panel auditInternal validity: medium · scope of inference: Symptomatic visual display terminal (computer) users with dry eye, benefit concentrated in those with low omega-3 index.Key limitations: symptom was a secondary outcome · within-group framing of significance
4 of 11 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A flatly null flagship trial balanced against numerous but lower-quality and non-independent positive trials places the claim in the uncertain band rather than supported or refuted.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Independent large-scale replication. The verdict hinges on a single null flagship trial [1] weighed against smaller, non-independent positives; no second comparably powered independent trial exists in the corpus. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A large, multicentre, independently funded, placebo-controlled RCT in general moderate-to-severe dry eye disease with a symptom primary endpoint and a demonstrably inert placebo.
Open question: Does oral omega-3 improve symptoms in a general moderate-to-severe dry eye population when tested in a second large independent trial? Why it is still open: Only one large trial [1] studied this population and it was null, while the positive trials are smaller and non-independent.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19